Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the market?
The market size of treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) has seen a significant increase in recent times. The market, which will reach $10.36 billion in 2024, is projected to increase to $13.32 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.5%. The impressive growth seen in the historical period is due to several factors such as the increasing occurrence of transthyretin amyloid cardiomyopathy, rising incidence of transthyretin amyloidosis in elderly patients, enhanced awareness among healthcare practitioners and patients, and progress in healthcare services and awareness initiatives.
What will be the market size in the future?
In the coming years, an extraordinary surge is expected in the market size for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The market will shoot up to a whopping $35.93 billion by 2029, growing at an impressive CAGR of 28.2%. The surge in the forecast period can be associated with factors like the growing occurrence of transthyretin amyloidosis, escalation in neuropathic disorder diagnosis, an increasing aging population demographic, rising request for specific drugs to treat the rare disorder symptoms, coupled with an increased demand in the healthcare sector. The future will be marked by significant trends, such as the emergence of new diagnostic technologies, the inception of inventive therapy management techniques, novel and focused treatments for transthyretin amyloidosis, and advancements in diagnostic and cardiac MRI techniques.
Get your market report here!
What are the major factors driving growth in the market?
The escalating occurrence of long-lasting ailments, which evolve slowly and often necessitate ongoing healthcare support, is anticipated to spur the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. The increased occurrence of such conditions could be due to factors including an aging populace, inactive lifestyles, poor dietary habits, growing obesity issues, and the presence of environmental pollutants. Transthyretin amyloid cardiomyopathy treatment contributes by steadying transthyretin, lowering amyloid accumulation, enhancing cardiac function, and easing symptoms to more effectively manage associated chronic diseases. As per the World Health Organization, a United Nations-specialized agency based in Switzerland, there were 41 million deaths in September 2023, accounting for 74% of annual deaths caused by non-communicable diseases or chronic ailments. On a global scale, cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes caused 17.9 million, 9.3 million, 4.1 million, and 2.0 million deaths respectively. Hence, the ever-increasing occurrence of chronic diseases is powering the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
What key areas define the segmentation of the global market?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
Who are the dominant players expanding their reach in the market?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG
What key trends are currently impacting the market’s development?
Leading corporations in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are concentrating their efforts on creating new and unique treatments for ATTR-CM. This includes oral medication prescriptions that target and stabilize transthyretin (TTR) proteins or decrease the accumulation of amyloid fibril in the heart. Oral prescription medication, often in the form of capsules, tablets, or liquid solutions, is typically prescribed by a healthcare provider. For example, BridgeBio Pharma Inc., a biotech firm based in the United States, obtained approval from the U.S. Food and Drug Administration in November 2024 for Attruby (acoramidis) to treat adults suffering from transthyretin amyloid cardiomyopathy (ATTR-CM). This helps stabilize the TTR protein and reduces cardiovascular-related fatalities and hospitalizations. Clinical tests have demonstrated that it is easily tolerated and offers quick benefits by addressing the root cause of the disorder.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304
Which regions are emerging as leaders in the market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Hepatitis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2025
Hepatitis Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
